Skip to main content
. 2019 Apr 24;41(1):284–293. doi: 10.1080/0886022X.2019.1597736

Table 1.

Patient clinical characteristics.

Clinical characteristics
Age (years) 70 ± 11
Male gender 57 (58.2%)
Height (cm) 159.3 ± 8.6
Body weight (kg) 59.6 ± 11.9
Body mass index 23.5 ± 4.4
SBP (mmHg) 138.2 ± 23
DBP (mmHg) 78.6 ± 14.8
Heart rate (beats/min) 76.5 ± 15.3
WBC (×102/μL) 61.6 ± 17.9
 Neut (%) 63.2 ± 9.5
 Lymph (%) 26.6 ± 8.9
 Mono (%) 6.0 ± 1.8
 Eosino (%) 3.6 ± 2.7
 Baso (%) 0.6 ± 0.4
 Neutrophil/lymphocyte 2.8 ± 1.5
 Log-NLR 0.4 ± 0.2
Plt (×104/μL) 20.3 ± 5.5
RBC (×104/μL) 428 ± 67
Hb (g/dL) 13.0 ± 2.1
MCV (fL) 92.4 ± 4.9
RDW-CV 13.8 ± 1.1
eGFR (mL/min/1.73m2 60.4 ± 27.1
Comorbidity
 Hypertension 74 (75.5%)
 Diabetes mellitus 43 (43.9%)
 Dyslipidemia 47 (48.0%)
 Heart failure 18 (18.4%)
 Angina pectoris 25 (25.5%)
 Old myocardial infarction 22 (22.4%)
 History of PCI 20 (20.4%)
 Cerebral infarction 13 (13.3%)
 Cerebral hemorrhage 2 (2.0%)
 Peripheral artery disease 24 (24.5%)
 History of gastroduodenal ulcer 7 (7.1%)
 Reflux esophagitis 9 (9.2%)
Medication
 Antiplatelet agents 52 (53.1%)
 ARB 51 (52.0%)
 Calcium channel blockers 46 (46.9%)
 β-blockers 38 (38.8%)
 Diuretic agents 32 (32.7%)
 Statins 30 (30.6%)
 PPI 30 (30.6%)
 Oral hypoglycemic agents 19 (19.4%)
 H2-blockers 15 (15.3%)
 Warfarin 13 (13.3%)
 ACEI 11 (11.2%)
 Uric acid-lowering agents 7 (7.1%)
 Insulin 3 (3.1%)

Data given as mean ± SD or n (%). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; H2-blocker: histamine type 2 receptor blocker; Hb: hemoglobin; Ht: hematocrit; MCV: mean corpuscular volume; log-NLR: log-transformed neutrophil/lymphocyte ratio; PCI: percutaneous coronary intervention; Plt: platelet; PPI: proton pump inhibitor; RBC: red blood cells; RDW-CV: coefficient of variation of red cell distribution width; SBP: systolic blood pressure; WBC: white blood cells.